Delaying ageing of the skin – JEL0305
Carocell Bio is more than just a name; it’s an evolution in skin care.
Spearheading a movement, we are harnessing peptide-based anti-inflammatory technology to more safely treat skin-related conditions. Discovered by AstraZeneca, our peptides are a weapon against skin-related inflammation and ageing.
As a bridge between innovating science and unmet patient needs, we are set to alter the course of treatments available, delivering tangible benefits demonstrated in both cellular and human biopsy studies.
One of the major changes that occur during ageing is the dysregulation of the immune response, leading to a chronic systemic inflammatory state. Among the dysregulated proinflammatory mediators, cytokines and chemokines are major culprits in the development of chronic inflammation and the immunosenescence process.
In the ageing literature, there are currently two major hypotheses related to age-related inflammation: inflammageing (6,7) and molecular inflammation (3,8,9,10). These two are complementary to each other to a large extent but differ in their focus on age-related inflammatory phenomena. Chronic inflammation is so widely and deeply involved in many age-related chronic disorders such as atherosclerosis, diabetes, obesity, sarcopenia, and Alzheimer’s disease (10), it opens the arena for novel therapeutics, such as Carocell Bio’s novel safe and effective peptides. Skin ageing is a logical place to start.
It is now recognised that inflammation is the cause of senescence/ageing (1-10). It is hypothesised that chronic therapy with the topical anti-inflammatory peptide, JEL0305, permitted because of safety as well as efficacy, could be used to delay ageing of the skin to which it is applied.
Clinical trials will help prove this exciting prospect that could open a cosmetic side or licensing opportunity for Carocell Bio.
- Freire MO et al, 2013
- Chen M, et al, 2015
- Chung HY et al, 2006
- Bruunsgaard H et al, 2003
- Gordon CJ et al, 2011
- Franceschi C et al, 2000
- Franceschi C et al, 2007
- Chung HY et al, 2000
- Chung HY et al, 2002
- Chung HY et al, 2011
Find out more about our therapeutic peptides and how they can reduce inflammation in a host of serious inflammatory diseases
For further information and access to detailed documentation, please get in touch